Cargando…
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Acquired resistance to epidermal growth factor receptor (EGFR) targeted antibodies represents a clinical challenge in the treatment of gastrointestinal tumors such as metastatic colorectal cancer, but its molecular mechanisms are incompletely understood. We scanned KRAS exon 2/3/4, NRAS exon 2/3/4 a...
Autores principales: | Braig, Friederike, März, Manuela, Schieferdecker, Aneta, Schulte, Alexander, Voigt, Mareike, Stein, Alexander, Grob, Tobias, Alawi, Malik, Indenbirken, Daniela, Kriegs, Malte, Engel, Erik, Vanhoefer, Udo, Grundhoff, Adam, Loges, Sonja, Riecken, Kristoffer, Fehse, Boris, Bokemeyer, Carsten, Binder, Mascha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494921/ https://www.ncbi.nlm.nih.gov/pubmed/26059438 |
Ejemplares similares
-
Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014) -
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
por: Braig, Friederike, et al.
Publicado: (2016) -
Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
por: Tintelnot, Joseph, et al.
Publicado: (2020) -
Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
por: Watanabe, Shoichi, et al.
Publicado: (2017) -
Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)